ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1200

Runx2 Deletion in Myeloid Cells Exaggerates Kidney Fibrosis Through Increase in Siglec-F+ Neutrophils

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Sakai, Hibiki, Osaka Daigaku, Suita, Osaka Prefecture, Japan
  • Yamamoto, Maki, Osaka Daigaku, Suita, Osaka Prefecture, Japan
  • Tanaka, Shota, Osaka Daigaku, Suita, Osaka Prefecture, Japan
  • Okada, Yoshiaki, Osaka Daigaku, Suita, Osaka Prefecture, Japan
  • Fujio, Yasushi, Osaka Daigaku, Suita, Osaka Prefecture, Japan
  • Obana, Masanori, Osaka Daigaku, Suita, Osaka Prefecture, Japan
Background

Runt-related transcription factor 2 (Runx2) is widely known as a transcription factor for bone formation and vascular calcification. Our previous study demonstrated that Runx2 in myeloid cells, including neutrophils and macrophages, prevents adverse cardiac fibrosis after myocardial infarction; however, the pathophysiological role of myeloid Runx2 in kidney fibrosis is unknown.

Methods

Runx2 expression in human and murine fibrotic kidneys was examined using immunohistochemistry and flow cytometry with anti-Runx2 antibody. Myeloid cell-specific Runx2 knockout (CKO) mice were subjected to unilateral ureteral obstruction (UUO). Kidney fibrosis was evaluated using Masson’s trichrome staining, measuring hydroxyproline level, and immunofluorescence analysis with anti-α-SMA antibody. For single-cell RNA sequencing (scRNA-seq), myeloid cells were isolated from murine kidneys subjected to UUO by magnetic cell sorting. To examine the effects of Siglec-F+ neutrophils on kidney fibrosis, CKO mice were subjected to UUO and treated with the Siglec-F depletion antibody or isotype control antibody (40 ug/head, i.p. at day 2 and 4 after UUO).

Results

Public scRNA-seq data, immunohistochemistry, and flow cytometry demonstrated that Runx2 expression was upregulated in myeloid cells of murine fibrotic kidneys. Runx2 expression was also upregulated in human kidneys with end-stage renal disease. CKO mice showed increased fibrosis area and hydroxyproline content compared with control mice day 7 after UUO (fibrosis area: fl/fl; 8.30±0.87 um2/field, CKO; 10.87±1.23 um2/field, n = 5 for fl/fl, n = 7 for CKO). Additionally, the α-SMA-positive area was higher in CKO mice than in control mice. scRNA-seq revealed that Runx2 knockout in myeloid cells affected neutrophil properties, such as increased Siglec-F-positive neutrophils. Treatment with the Siglec-F depletion antibody reduced kidney fibrosis in CKO mice after UUO.

Conclusion

Runx2 deletion in myeloid cells exaggerates kidney fibrosis through an increase in the number of Siglec-F+ neutrophils, providing a novel insight into the pathogenesis of kidney fibrosis.

Digital Object Identifier (DOI)